Molnupiravir is a promising antiviral drug that is currently in clinical trials for the treatment of COVID-19. However, like all drugs, it may contain impurities. Impurities are substances that are present in small amounts in the drug and can affect its purity, potency, and safety. Molnupiravir impurities may include starting materials, intermediates, degradation products, and residual solvents. It is important to identify and quantify these impurities to ensure the quality and safety of the drug. Regulatory agencies such as the FDA and EMA have strict guidelines on the acceptable levels of impurities in drugs.
